Laboratorios Farmaceuticos ROVI (ROVI) - Net Assets
Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) has net assets worth €632.80 Million EUR (≈ $739.81 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€922.07 Million ≈ $1.08 Billion USD) and total liabilities (€289.27 Million ≈ $338.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Laboratorios Farmaceuticos ROVI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €632.80 Million |
| % of Total Assets | 68.63% |
| Annual Growth Rate | 18.06% |
| 5-Year Change | 55.62% |
| 10-Year Change | 252.91% |
| Growth Volatility | 35062023.76 |
Laboratorios Farmaceuticos ROVI - Net Assets Trend (2003–2024)
This chart illustrates how Laboratorios Farmaceuticos ROVI's net assets have evolved over time, based on quarterly financial data. Also explore how large is Laboratorios Farmaceuticos ROVI's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Laboratorios Farmaceuticos ROVI (2003–2024)
The table below shows the annual net assets of Laboratorios Farmaceuticos ROVI from 2003 to 2024. For live valuation and market cap data, see Laboratorios Farmaceuticos ROVI (ROVI) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €581.54 Million ≈ $679.88 Million |
+7.00% |
| 2023-12-31 | €543.49 Million ≈ $635.40 Million |
+4.24% |
| 2022-12-31 | €521.38 Million ≈ $609.55 Million |
+10.70% |
| 2021-12-31 | €470.98 Million ≈ $550.62 Million |
+26.03% |
| 2020-12-31 | €373.70 Million ≈ $436.89 Million |
+15.92% |
| 2019-12-31 | €322.39 Million ≈ $376.90 Million |
+12.15% |
| 2018-12-31 | €287.47 Million ≈ $336.08 Million |
+49.97% |
| 2017-12-31 | €191.69 Million ≈ $224.10 Million |
+4.52% |
| 2016-12-31 | €183.41 Million ≈ $214.42 Million |
+11.30% |
| 2015-12-31 | €164.78 Million ≈ $192.65 Million |
+3.98% |
| 2014-12-31 | €158.47 Million ≈ $185.27 Million |
+9.70% |
| 2013-12-31 | €144.46 Million ≈ $168.89 Million |
+14.25% |
| 2012-12-31 | €126.45 Million ≈ $147.83 Million |
+10.94% |
| 2011-12-31 | €113.98 Million ≈ $133.26 Million |
+9.46% |
| 2010-12-31 | €104.13 Million ≈ $121.74 Million |
+45.65% |
| 2009-12-31 | €71.50 Million ≈ $83.59 Million |
+47.60% |
| 2008-12-31 | €48.44 Million ≈ $56.63 Million |
-6.71% |
| 2007-12-31 | €51.92 Million ≈ $60.70 Million |
+101.18% |
| 2006-12-31 | €25.81 Million ≈ $30.17 Million |
-100.00% |
| 2005-12-31 | €4.80 Trillion ≈ $5.61 Trillion |
+164642253.70% |
| 2004-12-31 | €2.92 Million ≈ $3.41 Million |
-83.62% |
| 2003-12-31 | €17.80 Million ≈ $20.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Laboratorios Farmaceuticos ROVI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23792.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €486.21 Million | 85.00% |
| Common Stock | €3.07 Million | 0.54% |
| Other Comprehensive Income | €650.00K | 0.11% |
| Other Components | €82.09 Million | 14.35% |
| Total Equity | €572.03 Million | 100.00% |
Laboratorios Farmaceuticos ROVI Competitors by Market Cap
The table below lists competitors of Laboratorios Farmaceuticos ROVI ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Paladin Energy Ltd
AU:PDN
|
$3.81 Billion |
|
Huaan Securities Co Ltd
SHG:600909
|
$3.81 Billion |
|
KENON HLDGS LTD
F:76N
|
$3.81 Billion |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ:AMRX
|
$3.81 Billion |
|
Capricorn Metals Ltd
AU:CMM
|
$3.80 Billion |
|
Kilroy Realty Corp
NYSE:KRC
|
$3.80 Billion |
|
Vontobel Holding
SW:VONN
|
$3.80 Billion |
|
Cosco Shipping Development Co Ltd
SHG:601866
|
$3.80 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laboratorios Farmaceuticos ROVI's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 539,387,000 to 572,028,000, a change of 32,641,000 (6.1%).
- Net income of 136,881,000 contributed positively to equity growth.
- Dividend payments of 56,451,000 reduced retained earnings.
- Share repurchases of 89,708,000 reduced equity.
- New share issuances of 41,921,000 increased equity.
- Other comprehensive income decreased equity by 2,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €136.88 Million | +23.93% |
| Dividends Paid | €56.45 Million | -9.87% |
| Share Repurchases | €89.71 Million | -15.68% |
| Share Issuances | €41.92 Million | +7.33% |
| Other Comprehensive Income | €-2.00K | -0.0% |
| Total Change | €- | 6.05% |
Book Value vs Market Value Analysis
This analysis compares Laboratorios Farmaceuticos ROVI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.65x to 7.12x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €21.72 | €79.40 | x |
| 2005-12-31 | €29954.19 | €79.40 | x |
| 2006-12-31 | €0.52 | €79.40 | x |
| 2007-12-31 | €1.04 | €79.40 | x |
| 2008-12-31 | €0.97 | €79.40 | x |
| 2009-12-31 | €1.43 | €79.40 | x |
| 2010-12-31 | €2.09 | €79.40 | x |
| 2011-12-31 | €2.29 | €79.40 | x |
| 2012-12-31 | €2.55 | €79.40 | x |
| 2013-12-31 | €2.90 | €79.40 | x |
| 2014-12-31 | €3.19 | €79.40 | x |
| 2015-12-31 | €3.33 | €79.40 | x |
| 2016-12-31 | €3.72 | €79.40 | x |
| 2017-12-31 | €3.89 | €79.40 | x |
| 2018-12-31 | €5.61 | €79.40 | x |
| 2019-12-31 | €5.84 | €79.40 | x |
| 2020-12-31 | €6.75 | €79.40 | x |
| 2021-12-31 | €8.50 | €79.40 | x |
| 2022-12-31 | €9.73 | €79.40 | x |
| 2023-12-31 | €10.41 | €79.40 | x |
| 2024-12-31 | €11.16 | €79.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laboratorios Farmaceuticos ROVI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.93%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.92%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 1.45x
- Recent ROE (23.93%) is below the historical average (29.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 145.70% | 22.44% | 0.89x | 7.25x | €1.47 Billion |
| 2005 | 60.90% | 11.62% | 0.96x | 5.44x | €762.36 Billion |
| 2006 | 19.61% | 6.44% | 1.03x | 2.95x | €2.48 Million |
| 2007 | 28.81% | 14.85% | 0.90x | 2.16x | €9.77 Million |
| 2008 | 48.60% | 18.46% | 1.06x | 2.49x | €18.70 Million |
| 2009 | 32.36% | 20.09% | 0.69x | 2.32x | €15.99 Million |
| 2010 | 23.61% | 15.49% | 0.75x | 2.04x | €14.17 Million |
| 2011 | 15.90% | 9.81% | 0.81x | 2.00x | €6.73 Million |
| 2012 | 15.43% | 9.66% | 0.91x | 1.76x | €6.87 Million |
| 2013 | 15.94% | 10.58% | 0.92x | 1.63x | €8.58 Million |
| 2014 | 15.22% | 10.13% | 0.91x | 1.65x | €8.27 Million |
| 2015 | 12.02% | 8.05% | 0.93x | 1.60x | €3.33 Million |
| 2016 | 14.22% | 9.84% | 0.92x | 1.57x | €7.75 Million |
| 2017 | 8.99% | 6.25% | 0.92x | 1.56x | €-1.93 Million |
| 2018 | 6.22% | 5.90% | 0.75x | 1.40x | €-10.85 Million |
| 2019 | 12.18% | 10.30% | 0.75x | 1.59x | €7.03 Million |
| 2020 | 16.34% | 14.54% | 0.73x | 1.54x | €23.69 Million |
| 2021 | 32.50% | 23.60% | 0.89x | 1.56x | €105.98 Million |
| 2022 | 38.40% | 24.42% | 0.93x | 1.69x | €147.67 Million |
| 2023 | 31.58% | 20.53% | 1.04x | 1.48x | €116.40 Million |
| 2024 | 23.93% | 17.92% | 0.92x | 1.45x | €79.68 Million |
Industry Comparison
This section compares Laboratorios Farmaceuticos ROVI's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $572,391,250
- Average return on equity (ROE) among peers: -16.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laboratorios Farmaceuticos ROVI (ROVI) | €632.80 Million | 145.70% | 0.46x | $3.81 Billion |
| Almirall S.A. (ALM) | $1.34 Billion | 33.48% | 0.90x | $2.63 Billion |
| Faes Farma SA (FAE) | $747.70 Million | 10.65% | 0.79x | $1.50 Billion |
| Labiana Health S.A. (LAB) | $7.74 Million | -115.49% | 6.85x | $32.50 Million |
| Laboratorio Reig Jofre S.A (RJF) | $194.55 Million | 4.17% | 0.65x | $221.39 Million |
About Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more